NoBACZ Healthcare Secures £4.8M: Revolutionizing Animal Wound Care with Innovative 'Liquid Bandage'
October 3, 2025, 3:41 am
NoBACZ Healthcare, a pioneering Cambridge spinout, has secured a vital £4.8 million funding round. This investment accelerates the global deployment of its 'liquid bandage' technology. The innovative solution offers sustainable, antibiotic-free wound care for livestock and horses. It creates a robust, waterproof barrier, protecting against infection in demanding agricultural settings. This advanced method replaces traditional, often ineffective, antibiotic and cloth bandage treatments. Funds will boost product commercialization, new pipeline development, and exploration into human healthcare applications. This breakthrough promises to reshape animal welfare and significantly reduce antibiotic usage across the globe.
---
Animal agriculture faces significant challenges. Effective wound care remains a critical concern for livestock and horses. Traditional methods often fall short. They lead to prolonged suffering and substantial economic loss. Now, a revolutionary technology emerges from Cambridge. NoBACZ Healthcare offers a sustainable, antibiotic-free solution. The company recently secured £4.8 million in funding. This investment propels its innovative 'liquid bandage' technology forward.
Current animal wound treatment relies heavily on antibiotics. Cloth bandages then cover these applications. This approach presents multiple flaws. Agricultural environments are often harsh. Slurry and contaminants abound. These elements easily wash away antibiotics. Bandages themselves can become breeding grounds for infection. Farmers battle a losing fight against persistent issues. Wounds remain open. Healing slows. Infection risk escalates. A quarter of all cows, for instance, suffer from digital dermatitis at any given time. This painful disease costs farmers dearly.
NoBACZ Healthcare was founded to address these failings. Dr. Jonathan Powell and Dr. Nuno Faria spearheaded the effort. Their research at the University of Cambridge’s Department of Veterinary Medicine laid the groundwork. They studied how bodies naturally build and utilize mineral structures. This scientific inquiry led to a breakthrough. It yielded their patented 'liquid bandage' technology.
The result is a transformative product. It takes the form of a robust, flexible, and waterproof coating. Application is versatile. It can be a gel, a dip, or a spray. This coating instantly creates a protective barrier. It seals out slurry and harmful bacteria. Wounds then heal without infection risk. This holds true even in the most challenging conditions. The coating boasts impressive durability. Yet, it remains biodegradable. It is safe for the food chain. Application is intuitive. Crucially, it contains no antibiotics.
This innovative solution marks a pivotal shift. It moves away from outdated, ineffective treatments. The 'liquid bandage' tackles infections proactively. It does so without contributing to antibiotic resistance. This offers profound benefits. Animal welfare improves dramatically. Farmers see reduced losses. The entire agricultural sector moves towards greater sustainability.
Independent large-scale studies validate its effectiveness. A significant Flock Health trial took place. It involved 6,840 lambs. Results were conclusive. Lambs treated with the NoBACZ technology showed significantly lower mortality rates. They also achieved higher market weights. These outcomes surpassed industry standards. The data speaks for itself. This technology works.
The company is not new to the global stage. NoBACZ Healthcare already operates internationally. Key markets include the UK, Ireland, and Europe. Launches are also underway in New Zealand, the USA, and Australia. The global commercialization strategy is clear. It aims for widespread adoption. This expansion will bring critical wound care to more animals. It will support more farmers worldwide.
The recent £4.8 million funding round fuels this ambitious growth. The Yield Lab led the investment. Other notable participants included Adjuvo, ACF Investors, the University of Cambridge, Parkwalk, The FSE Group, and Cambridge Enterprise Ventures. This broad support underscores confidence. Investors recognize the technology's potential. They see its global impact.
The capital infusion has a clear purpose. It will finalize NoBACZ’s new pipeline of products. It will accelerate commercialization efforts. Global distribution of existing products will also expand rapidly. This means more access to the 'liquid bandage.' More animals will benefit. More farmers will find relief.
The company’s vision extends beyond veterinary medicine. A parallel product roadmap is in development. NoBACZ Healthcare is actively defining its human product opportunity. The core technology, rooted in natural mineral structures, holds promise for human applications. This opens new frontiers. It positions NoBACZ for broader healthcare impact.
Transforming healthcare solutions for a sustainable future is the company’s driving force. Reducing antibiotic use is a core principle. This commitment guides every development. It shapes every market strategy. The current moment is exciting. It represents a pivotal point in the company's journey. Continued growth and innovation are guaranteed.
NoBACZ Healthcare exemplifies modern innovation. It solves real-world problems. It champions sustainable practices. Its 'liquid bandage' technology offers a superior alternative. It improves animal health. It reduces reliance on antibiotics. It safeguards the food chain. This Cambridge spinout is poised for significant global influence. It is changing how the world approaches wound care.
---
Animal agriculture faces significant challenges. Effective wound care remains a critical concern for livestock and horses. Traditional methods often fall short. They lead to prolonged suffering and substantial economic loss. Now, a revolutionary technology emerges from Cambridge. NoBACZ Healthcare offers a sustainable, antibiotic-free solution. The company recently secured £4.8 million in funding. This investment propels its innovative 'liquid bandage' technology forward.
Current animal wound treatment relies heavily on antibiotics. Cloth bandages then cover these applications. This approach presents multiple flaws. Agricultural environments are often harsh. Slurry and contaminants abound. These elements easily wash away antibiotics. Bandages themselves can become breeding grounds for infection. Farmers battle a losing fight against persistent issues. Wounds remain open. Healing slows. Infection risk escalates. A quarter of all cows, for instance, suffer from digital dermatitis at any given time. This painful disease costs farmers dearly.
NoBACZ Healthcare was founded to address these failings. Dr. Jonathan Powell and Dr. Nuno Faria spearheaded the effort. Their research at the University of Cambridge’s Department of Veterinary Medicine laid the groundwork. They studied how bodies naturally build and utilize mineral structures. This scientific inquiry led to a breakthrough. It yielded their patented 'liquid bandage' technology.
The result is a transformative product. It takes the form of a robust, flexible, and waterproof coating. Application is versatile. It can be a gel, a dip, or a spray. This coating instantly creates a protective barrier. It seals out slurry and harmful bacteria. Wounds then heal without infection risk. This holds true even in the most challenging conditions. The coating boasts impressive durability. Yet, it remains biodegradable. It is safe for the food chain. Application is intuitive. Crucially, it contains no antibiotics.
This innovative solution marks a pivotal shift. It moves away from outdated, ineffective treatments. The 'liquid bandage' tackles infections proactively. It does so without contributing to antibiotic resistance. This offers profound benefits. Animal welfare improves dramatically. Farmers see reduced losses. The entire agricultural sector moves towards greater sustainability.
Independent large-scale studies validate its effectiveness. A significant Flock Health trial took place. It involved 6,840 lambs. Results were conclusive. Lambs treated with the NoBACZ technology showed significantly lower mortality rates. They also achieved higher market weights. These outcomes surpassed industry standards. The data speaks for itself. This technology works.
The company is not new to the global stage. NoBACZ Healthcare already operates internationally. Key markets include the UK, Ireland, and Europe. Launches are also underway in New Zealand, the USA, and Australia. The global commercialization strategy is clear. It aims for widespread adoption. This expansion will bring critical wound care to more animals. It will support more farmers worldwide.
The recent £4.8 million funding round fuels this ambitious growth. The Yield Lab led the investment. Other notable participants included Adjuvo, ACF Investors, the University of Cambridge, Parkwalk, The FSE Group, and Cambridge Enterprise Ventures. This broad support underscores confidence. Investors recognize the technology's potential. They see its global impact.
The capital infusion has a clear purpose. It will finalize NoBACZ’s new pipeline of products. It will accelerate commercialization efforts. Global distribution of existing products will also expand rapidly. This means more access to the 'liquid bandage.' More animals will benefit. More farmers will find relief.
The company’s vision extends beyond veterinary medicine. A parallel product roadmap is in development. NoBACZ Healthcare is actively defining its human product opportunity. The core technology, rooted in natural mineral structures, holds promise for human applications. This opens new frontiers. It positions NoBACZ for broader healthcare impact.
Transforming healthcare solutions for a sustainable future is the company’s driving force. Reducing antibiotic use is a core principle. This commitment guides every development. It shapes every market strategy. The current moment is exciting. It represents a pivotal point in the company's journey. Continued growth and innovation are guaranteed.
NoBACZ Healthcare exemplifies modern innovation. It solves real-world problems. It champions sustainable practices. Its 'liquid bandage' technology offers a superior alternative. It improves animal health. It reduces reliance on antibiotics. It safeguards the food chain. This Cambridge spinout is poised for significant global influence. It is changing how the world approaches wound care.